State Street’s RAPT Therapeutics RAPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-639,804
Closed -$21.7M 4326
2025
Q4
$21.7M Buy
639,804
+602,421
+1,611% +$18.7M ﹤0.01% 2228
2025
Q3
$964K Buy
37,383
+18,321
+96% +$240K ﹤0.01% 3520
2025
Q2
$152K Sell
19,062
-72,917
-79% -$556K ﹤0.01% 3892
2025
Q1
$898K Buy
91,979
+4,573
+5% +$45K ﹤0.01% 3455
2024
Q4
$1.1M Buy
87,406
+2,467
+3% +$31.3K ﹤0.01% 3469
2024
Q3
$1.37M Buy
84,939
+966
+1% +$19.5K ﹤0.01% 3425
2024
Q2
$2.05M Buy
83,973
+1,548
+2% +$71.5K ﹤0.01% 3311
2024
Q1
$5.92M Sell
82,425
-99,395
-55% -$13.8M ﹤0.01% 2860
2023
Q4
$36.1M Buy
181,820
+6,007
+3% +$744K ﹤0.01% 1879
2023
Q3
$23.4M Sell
175,813
-36,943
-17% -$6.03M ﹤0.01% 2068
2023
Q2
$31.8M Buy
212,756
+7,875
+4% +$1.23M ﹤0.01% 1948
2023
Q1
$30.1M Sell
204,881
-37,709
-16% -$7.63M ﹤0.01% 1968
2022
Q4
$38.4M Buy
242,590
+83,354
+52% +$13.3M ﹤0.01% 1818
2022
Q3
$30.6M Buy
159,236
+97,878
+160% +$18.5M ﹤0.01% 1932
2022
Q2
$8.96M Sell
61,358
-107,090
-64% -$14.3M ﹤0.01% 2794
2022
Q1
$29.6M Buy
168,448
+12,975
+8% +$2.45M ﹤0.01% 2118
2021
Q4
$45.7M Buy
155,473
+112,368
+261% +$30M ﹤0.01% 1869
2021
Q3
$10.7M Buy
43,105
+9,298
+28% +$2.46M ﹤0.01% 2855
2021
Q2
$8.6M Buy
33,807
+9,536
+39% +$1.78M ﹤0.01% 2991
2021
Q1
$4.31M Buy
24,271
+99
+0.4% +$16.3K ﹤0.01% 3110
2020
Q4
$3.82M Buy
24,172
+881
+4% +$192K ﹤0.01% 3099
2020
Q3
$6M Buy
23,291
+1,047
+5% +$232K ﹤0.01% 2693
2020
Q2
$5.16M Buy
22,244
+19,227
+637% +$2.97M ﹤0.01% 2742
2020
Q1
$513K Buy
3,017
+1,792
+146% +$408K ﹤0.01% 3446
2019
Q4
$271K Buy
+1,225
New +$225K ﹤0.01% 3600

State Street's RAPT Position: Q1 2026 in Review

State Street sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 639,804 shares — an estimated $21.7M sold.

State Street first reported a position in RAPT in Q4 2019 and held it in 25 quarters. The position peaked at $45.7M in Q4 2021. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

  • State Street reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
  • State Street sold 639,804 RAPT Therapeutics shares in Q1 2026, an estimated $21.7M.
  • State Street first reported a position in RAPT Therapeutics in Q4 2019 and held it in 25 quarters.
  • State Street's RAPT Therapeutics position peaked at $45.7M in Q4 2021.
  • 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.